产品详情
仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Mitazalimab （ADC-1013; JNJ-64457107） is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells （DC）, to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment
您的位置：
